Patron Exim Ltd
Incorporated in 1992, Patron Exim Ltd is in the business of trading pharma products and commission agent in pharma products, etc.[1]
- Market Cap ₹ 14.2 Cr.
- Current Price ₹ 6.12
- High / Low ₹ 9.80 / 4.80
- Stock P/E 203
- Book Value ₹ 16.9
- Dividend Yield 0.00 %
- ROCE 0.28 %
- ROE 0.18 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.36 times its book value
- Debtor days have improved from 349 to 91.6 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 2.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Trading - Chemicals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 3.88 | 12.95 | 6.58 | 24.36 | |
| 3.41 | 16.92 | 9.33 | 24.57 | |
| Operating Profit | 0.47 | -3.97 | -2.75 | -0.21 |
| OPM % | 12.11% | -30.66% | -41.79% | -0.86% |
| 1.14 | 5.93 | 3.65 | 0.32 | |
| Interest | 0.19 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | 1.41 | 1.95 | 0.90 | 0.11 |
| Tax % | 30.50% | 29.23% | 25.56% | 36.36% |
| 0.99 | 1.38 | 0.67 | 0.07 | |
| EPS in Rs | 0.60 | 0.29 | 0.03 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 84% |
| TTM: | 270% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -59% |
| TTM: | -90% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 5.34 | 23.18 | 23.18 | 23.18 |
| Reserves | 0.00 | 15.29 | 15.96 | 16.03 |
| 0.00 | 0.03 | 0.26 | 0.23 | |
| 5.62 | -0.02 | 5.93 | 4.81 | |
| Total Liabilities | 10.96 | 38.48 | 45.33 | 44.25 |
| 0.01 | 0.01 | 0.01 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 8.67 | 8.67 | 8.76 |
| 10.95 | 29.80 | 36.65 | 35.48 | |
| Total Assets | 10.96 | 38.48 | 45.33 | 44.25 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.76 | -22.81 | -0.26 | -0.01 | |
| 0.00 | -8.68 | 0.00 | 0.00 | |
| -0.76 | 31.78 | 0.23 | -0.03 | |
| Net Cash Flow | 0.00 | 0.29 | -0.04 | -0.04 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 710.24 | 393.75 | 561.92 | 91.55 |
| Inventory Days | 336.84 | 89.82 | 308.75 | 42.61 |
| Days Payable | 537.21 | -23.95 | 625.34 | 61.07 |
| Cash Conversion Cycle | 509.87 | 507.52 | 245.33 | 73.09 |
| Working Capital Days | 500.46 | 832.03 | 1,689.10 | 587.51 |
| ROCE % | 8.90% | 2.31% | 0.28% |
Documents
Announcements
-
Statement Of Deviation Or Variation Under Regulation 32(1) Of The SEBI (LODR) Regulations, 2015 Read With Applicable SEBI Circular
23 May - No deviation in utilization of Rs.16.68 Cr IPO funds as per prospectus till Mar 31, 2025.
-
Board Meeting Outcome for Audited Financial Results For The Year Ended March 31, 2025
23 May - Audited FY25 results approved; auditor notes tax dues, related party loans, governance non-compliance, and litigation risks.
- Audited Financial Results For The Year Ended March 31, 2025 23 May
-
Board Meeting Intimation for 1)To Consider And Approve The Audited Standalone Financial Results Along With The Statutory Auditors' Report Thereon For The Half Year And Year Ended On March 31, 2025; And
Ii) To Consider Any Other Business With The Permission Of The Chair.
19 May - Board meeting postponed to May 23 for audited financial results approval.
-
Board Meeting Intimation for Prior Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
8 May - Board meeting on May 19 to approve audited financial results for FY and H1 ending March 31, 2025.
Business Overview:[1]
PEL used to do trading of timber, cement sheets and other ancillary business, and also in surgical & non-surgical articles. Currently, company is an ISO 9001:2015, ISO 45001:2018, WHO-GMP, etc. certified trader and distributor of wide range of pharmaceutical raw material like Active Pharmaceutical Ingredients, Industrial, excipient, and solvents